Edition:
United States

Jazz Pharmaceuticals PLC (JAZZ.O)

JAZZ.O on Nasdaq

147.89USD
22 Sep 2017
Change (% chg)

-- (--)
Prev Close
$147.89
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
459,040
52-wk High
$163.75
52-wk Low
$95.80

Chart for

About

Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead... (more)

Overall

Beta: 1.07
Market Cap(Mil.): $8,883.01
Shares Outstanding(Mil.): 60.06
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 30.87 15.95
EPS (TTM): -- -- --
ROI: -- 14.31 15.19
ROE: -- 15.61 13.87

BRIEF-Jazz Pharma announces $500 mln offering of 1.50 pct exchangeable senior notes due 2024

* Jazz Pharmaceuticals Plc - ‍offering of $500 million aggregate principal amount of 1.50% exchangeable senior notes due 2024​

Aug 18 2017

BRIEF-Jazz Pharmac announces offering of $500 mln of exchangeable senior notes

* Jazz Pharmaceuticals announces offering of $500 million of exchangeable senior notes due 2024

Aug 17 2017

BRIEF-Jazz Pharmaceuticals Q2 adjusted earnings per share $2.56

* Jazz Pharmaceuticals announces second quarter 2017 financial results

Aug 08 2017

BRIEF-Jazz Pharmaceuticals announces FDA approval of Vyxeos

* Jazz Pharmaceuticals announces FDA approval of Vyxeos™ (Daunorubicin and Cytarabine) liposome for injection for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)

Aug 03 2017

BRIEF-Jazz Pharmaceuticals and XL-protein GmbH enter into license agreement

* Jazz Pharmaceuticals and XL-protein GmbH enter into a license agreement on PASylation technology to develop long-acting asparaginase product candidates

Jul 26 2017

BRIEF-Jazz Pharmaceuticals says on June 28, its unit entered into pharmacy master services agreement with Express Scripts specialty distribution services

* Jazz Pharmaceuticals says on June 28, its unit entered into a pharmacy master services agreement with express scripts specialty distribution services

Jul 03 2017

BRIEF-Jazz Pharmaceuticals presents data for study of JZP-110 in patients

* Jazz Pharmaceuticals presents data for the phase 3 tones 2 study of JZP-110 in patients with excessive sleepiness associated with narcolepsy

Jun 06 2017

BRIEF-Jazz Pharma to present key data on sleeping disorder drug at meeting

* Jazz pharmaceuticals to present phase 3 data on jzp-110, an investigational treatment for excessive sleepiness in patients with narcolepsy and with obstructive sleep apnea, during 31st annual sleep meeting Source text for Eikon: Further company coverage:

May 24 2017

BRIEF-Jazz pharmaceuticals announces Q1 2017 financial results

* Jazz pharmaceuticals announces first quarter 2017 financial results

May 09 2017

BRIEF-Jazz Pharmaceuticals announces positive results of JZP-110 study

* Jazz Pharmaceuticals announces positive results from the phase 3 tones 2 study of jzp-110 in narcolepsy patients with excessive sleepiness

Apr 26 2017

Earnings vs. Estimates